Japan's Megakaryon To Develop Mass-Producible Blood Drug
This article was originally published in PharmAsia News
Executive Summary
Megakaryon, a start-up Japanese bioventure, said it seeks to develop hemostatic drugs for the local and U.S. markets as early as 2018 to bypass sometimes risky donated blood products.